SCH-50911 is a selective GABABantagonist.[1] Its main applications are in pharmacology research.
SCH-50911 also acts as an anticonvulsant under normal conditions. SCH-50911 induces acute withdrawal syndrome in GHB-dependent rats, similar to the delirium tremens seen in human alcohol withdrawal, and can precipitate convulsions in GHB-dependent animals.[2]
^Blythin DJ, Kuo SC, Shue HJ, McPhail AT, Chapman RW, Kreutner W, et al. (July 1996). "Substituted morpholine-2S-acetic acid derivatives: Sch 50911 and related compounds as novel GABAB antagonists". Bioorganic & Medicinal Chemistry Letters. 6 (13): 1529–34. doi:10.1016/S0960-894X(96)00267-3.
^Quang LS, Colombo G, Lobina C, Maccioni P, Orru A, Gessa GL, et al. (August 2006). "Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines". Annals of the New York Academy of Sciences. 1074 (1): 545–58. Bibcode:2006NYASA1074..545Q. doi:10.1196/annals.1369.055. PMID17105952. S2CID86383425.